1. Home
  2. MBUU vs RIGL Comparison

MBUU vs RIGL Comparison

Compare MBUU & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Malibu Boats Inc.

MBUU

Malibu Boats Inc.

N/A

Current Price

$24.39

Market Cap

560.3M

Sector

Industrials

ML Signal

N/A

Logo Rigel Pharmaceuticals Inc.

RIGL

Rigel Pharmaceuticals Inc.

N/A

Current Price

$28.33

Market Cap

628.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MBUU
RIGL
Founded
1982
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
560.3M
628.4M
IPO Year
2013
2000

Fundamental Metrics

Financial Performance
Metric
MBUU
RIGL
Price
$24.39
$28.33
Analyst Decision
Hold
Strong Buy
Analyst Count
8
5
Target Price
$32.43
$43.20
AVG Volume (30 Days)
241.6K
332.3K
Earning Date
05-04-2026
05-22-2026
Dividend Yield
N/A
N/A
EPS Growth
127.74
1867.68
EPS
N/A
19.48
Revenue
$807,561,000.00
$294,282,000.00
Revenue This Year
N/A
$66.81
Revenue Next Year
$6.64
N/A
P/E Ratio
N/A
$1.48
Revenue Growth
N/A
64.15
52 Week Low
$24.07
$15.50
52 Week High
$39.65
$52.24

Technical Indicators

Market Signals
Indicator
MBUU
RIGL
Relative Strength Index (RSI) 26.54 26.38
Support Level $24.07 $27.23
Resistance Level $34.22 $31.26
Average True Range (ATR) 1.37 1.70
MACD -0.58 -0.55
Stochastic Oscillator 3.12 7.77

Price Performance

Historical Comparison
MBUU
RIGL

About MBUU Malibu Boats Inc.

Malibu Boats is a designer and manufacturer of power boats in the United States. It is a market leader in performance sport boats, sold under its Malibu and Axis brands. It acquired Cobalt Boats, a producer of sterndrive boats, in 2017, and Pursuit Boats, which makes high end offshore and outboard motorboats in 2018. In 2021, it purchased Maverick Boat Group, a seller of flat fishing boats, with exposure to bay, dual console, and center console boats. Malibu has also expanded into boat trailers and accessories, and in 2020, began producing its own engines for its performance sport boats.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Share on Social Networks: